Harvard Bioscience Inc (NASDAQ:HBIO) shares, rose in value, with the stock price up by 135.74% to the previous day’s close as strong demand from buyers drove the stock to $0.67.
Actively observing the price movement in the last trading, the stock closed the session at $0.28. Referring to stock’s 52-week performance, its high was $3.60, and the low was $0.28. On the whole, HBIO has fluctuated by 81.18% over the past month.
With the market capitalization of Harvard Bioscience Inc currently standing at about $29.63 million, investors are eagerly awaiting this quarter’s results, scheduled for in June.
Projections by analysts suggest varying estimates for the company’s quarterly revenue. Analysts have estimated the company’s revenue for the quarter at 86.5M, with a low estimate of 18M and a high estimate of 19.5M. Wall Street analysts also predicted that the company’s y-o-y revenues would reach 18.75M.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that HBIO’s technical picture suggests that short-term indicators denote the stock is a 50% Sell on average. However, medium-term indicators have put the stock in the category of 50% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the price of HBIO currently trading nearly 91.55% and 58.05% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 72.62, while the 7-day volatility ratio is showing 48.15% which for the 30-day chart, stands at 21.03%. Furthermore, Harvard Bioscience Inc (HBIO)’s beta value is 1.38, and its average true range (ATR) is 0.10.
A comparison of Harvard Bioscience Inc (HBIO) with its peers suggests the former has fared considerably weaker in the market. HBIO showed an intraday change of 135.74% in last session, and over the past year, it shrunk by -78.79%%.
Data on historical trading for Harvard Bioscience Inc (NASDAQ:HBIO) indicates that the trading volumes over the past 3 months, they’ve averaged 644.50K. According to company’s latest data on outstanding shares, there are 44.21 million shares outstanding.
Nearly 15.39% of Harvard Bioscience Inc’s shares belong to company insiders and institutional investors own 60.30% of the company’s shares. The stock has fallen by -68.24% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the HBIO stock heading into the next quarter.
